Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | PORCN | Q9H237 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19036549 | 0.91 | KMT2A (0.63) | POLBTHRBPORCNMAPTKMT2A | |
| SCHEMBL17626254 | 0.91 | PORCN (0.64) | POLBTHRBPORCNMAPTKMT2A | |
| SCHEMBL3266103 | 0.83 | MAPT (0.79) | POLBTHRBPORCNMAPTKMT2A | |
| SCHEMBL20161981 | 0.82 | RXFP1 (0.72) | POLBTHRBPORCNMAPTKMT2A | |
| SCHEMBL10114021 | 0.82 | TRPA1 (0.80) | POLBTHRBPORCNKMT2ARXFP1 | |
| SCHEMBL15384474 | 0.81 | POLB (0.65) | POLBTHRBPORCNMAPTKMT2A | |
| SCHEMBL21935441 | 0.80 | THRB (0.55) | POLBTHRBPORCNMAPTKMT2A | |
| SCHEMBL18166637 | 0.80 | HSD17B10 (0.67) | POLBTHRBPORCNMAPTKMT2A | |
| SCHEMBL4527599 | 0.80 | POLB (0.62) | POLBTHRBPORCNMAPTKMT2A | |
| SCHEMBL15384490 | 0.79 | POLB (0.64) | POLBTHRBPORCNMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | POLB 3878/4885THRB 1630/4885PORCN 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.